
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is a promising company in a growing market, with a focus on developing and selling innovative surgical robotics systems for urology. The company has faced some challenges in recent quarters, including slower procedure growth and restructuring under new leadership. However, it has outlined promising sales initiatives that could increase utilization and drive higher profitability, and the company's financials are still strong with a potential for future growth. While there are some risks to consider, such as competitive pressures and uncertainty in utilization and procedure trends, we believe the stock has the potential for significant upside in the long term.
Bears say
PROCEPT BioRobotics is facing multiple headwinds including restructuring of their sales force and likely decrease in demand due to alternative surgical and therapeutic options for BPH treatment. This is evident in their lower than expected handpiece sales and procedure growth, which has led to a decrease in their revenue forecast for 2026-2027. Furthermore, the increase in reimbursement for prostatic artery embolization (PAE) could lead to further shift away from Aquablation therapy, limiting growth prospects for the company. Additionally, potential competition from other surgical systems and pricing pressure could also have a negative impact on sales. As a result, we have a negative outlook on PROCEPT BioRobotics' stock.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares